Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
Future Oncology (London, England)|July 26, 2023
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myelomaAjai Chari, Elham Askari, Jo Caers, et al.
Cells|December 24, 2025
Comparing a Novel Anti-BCMA NanoCAR with a Conventional ScFv-Based CAR for the Treatment of Multiple MyelomaMégane Jassin, Chloé Onkelinx, Valentina Bocuzzi, et al.
The Oncologist|February 28, 2016
The Changing Landscape of Smoldering Multiple Myeloma: A European PerspectiveJo Caers, Carlos Fernández de Larrea, Xavier Leleu, et al.
International Journal of Hematology|June 27, 2020
High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severityGiovanni Caocci, Marco Vignetti, Andrea Patriarca, et al.
Scientific Reports|July 9, 2026
Infusion of human mesenchymal stromal cells during normothermic machine perfusion of porcine kidneys: a randomized, blinded, preclinical studyMargaux Navez, Nicholas Gilbo, Morgan Vandermeulen, et al.
Haematologica|July 28, 2018
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)Sara Bringhen, Alberto Milan, Claudio Ferri, et al.
Leukemia|July 25, 2018
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasiasMaria Gavriatopoulou, Pellegrino Musto, Jo Caers, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2020
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With LenalidomideBarbara Gamberi, Christian Berthou, Miguel Hernandez, et al.
Blood Advances|September 3, 2021
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myelomaArnold Bolomsky, Juho J Miettinen, Alina Malyutina, et al.
Breast Cancer Research : BCR|January 25, 2019
Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancerMarie-Julie Nokin, Justine Bellier, Florence Durieux, et al.
Pageof 10